Q-omics provides the consensus-scored DNAAF3 profile across patient tissues and cancer cell-line models. DNAAF3 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DNAAF3 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, DNAAF3 RNA expression shows 16,101 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, and KIRP as cancer lineages where DNAAF3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DNAAF3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DNAAF3 survival associations across molecular data types. DNAAF3 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DNAAF3 RNA expression–survival associations across cancer types. High DNAAF3 expression shows unfavorable associations in KIRC, LGG and UCS, but favorable associations in BRCA, UVM and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for DNAAF3 RNA expression.
This table summarizes DNAAF3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for DNAAF3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DNAAF3 shows lower tumor expression in KIRC, KICH and THCA and higher tumor expression in COAD, BLCA and KIRP. The KIRC box plot shows higher DNAAF3 RNA expression in normal versus tumor tissue (log2 FC = −0.627, t-test p < 0.001).
This table shows molecular features associated with DNAAF3 in patient tissues and cancer cell lines. In patient samples, DNAAF3 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, DNAAF3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
